A Phase 4 interventional study of Euvichol-S Oral Cholera Vaccine in Cholera Vaccination, sponsored by Albert B. Sabin Vaccine Institute. Recruiting at 1 site in Kenya. Open to participants aged 1 Year and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Albert B. Sabin Vaccine Institute · Phase 4, Interventional, and Health services research
Background: Despite efforts to control cholera, outbreaks continue to occur in Kenya. Oral cholera vaccines (OCVs) are a critical tool in cholera prevention strategies. This study evaluates the immunogenicity of extended dosing intervals for Euvichol-S, a WHO-prequalified OCV, in a Phase IV non-inferiority trial.
Overview Design: This trial is a parallel-group, open-label, randomized, non-inferiority study. It aims to compare the immune response of three dosing schedules of the Euvichol-S OCV: a standard 2-week interval, a 2-month interval, and a 12-month interval. The study will enroll 1071 participants, stratified by age into three groups (1-4 years, 5-14 years, 15+ years. The primary endpoint is the plasma vibriocidal geometric mean titer (GMT) measured two weeks after the second dose.
Primary Objective: To assess and compare the immune response to Euvichol-S measured by vibriocidal GMT two weeks after the second vaccine dose across different dosing intervals.
Study Sites: The study will be conducted in the Mukuru informal settlement in Nairobi, Kenya, a high-priority cholera hotspot area. The Kenya Medical Research Institute (KEMRI) will manage the study, leveraging its established relationship with the community.
Study Population: Inclusion criteria include residents of Mukuru ≥1 year, who are healthy as determined by medical history and physical examination. Exclusion criteria include pregnant women, severe malnutrition, and non-HIV immunosuppressive conditions or severe chronic diseases.
Study Interventions: Participants will be randomized to one of three dosing arms stratified by age: a standard 2-week interval, a 3-month interval, or an annual booster interval. Participants will receive the Euvichol-S OCV according to the assigned schedule. The follow-up period for participants will be 18 months, during which they will undergo regular scheduled visits and additional unscheduled visits as needed (i.e., standard dosing arm: six scheduled visits; 3-month interval arm: 7 visits; annual booster arm: 6 visits). Blood samples will be collected at each vaccination visit and 14 days later and at 6 months, 1 year and 18 months after enrollment to measure plasma vibriocidal GMT and other immunological markers. Older children in the PBMC cohort will have two additional samples collected five days after each vaccine dose and a larger blood volume (10mls) collected at 14 days after the second dose.
Outcome Measures: Primary outcome measures include the plasma vibriocidal GMT two weeks post-second dose. Secondary outcomes include antibody seroconversion rates, longitudinal GMT changes, incidence of cholera disease, and the safety profile of the vaccine. The PBMC sub-cohort will provide detailed insights into memory B cell and plasmablast responses.
Sample Size: The study will enroll 1071 participants with equal distribution across the three dosing arms and age strata. The PBMC sub-cohort will include 240 participants (40 per arm among 5-14 years, 40 per arm 1-4 years), with detailed immunological assessments.
Data Analysis: The immunogenicity of the vaccine across different dosing schedules will be compared to determine non-inferiority. Data will be analyzed descriptively to summarize the by-grade incidence of treatment-emergent adverse events (AEs), serious adverse events (SAEs), and other safety indicators.
Impact: This trial aims to generate evidence on the optimal dosing schedule for Euvichol-S OCV, potentially informing future vaccination strategies in cholera-endemic regions and improving cholera prevention in resource-limited settings.
Study Rationale Between October 2022 and February 2024, Kenya has experienced a cholera outbreak with over 10,000 reported cases and 166 deaths across 23 counties. Alarmingly, children under 10 years of age account for one-third of the documented cases, indicating their heightened vulnerability to the disease. In February 2023, Kenya vaccinated more than 2.2 million people with a single dose of oral cholera vaccine (OCV). However, this reactive campaign alone has proven insufficient to control the outbreak.
To address endemic cholera and prevent future outbreaks, the Kenya MoH has applied to Gavi, the Vaccine Alliance, to receive OCV for a preventive vaccination campaign in 2025 to 2028. Based on recent hotspot mapping led by partners in our consortium, the government plans to conduct mass vaccination campaigns in 94 hotspot sub-counties, reaching 19 million individuals. This campaign will mark the first national preventive campaign of OCV in East Africa. Insights gained will benefit not only Kenya but also neighbouring countries experiencing cholera outbreaks.
Studies evaluating the relative impact of campaigns utilizing two doses with extended intervals are limited. Additionally, prior studies assessing extended dosing intervals have not compared durability and immunogenicity within specific age groups, nor have they consistently included extended follow-up periods. Given the specific vulnerability of children, the Global Task Force for Cholera Control ranks research on optimal cholera vaccine schedules for children one to five years as the highest priority in the Cholera Roadmap Research Agenda.
Vaccination with OCV is a proven, effective strategy to prevent cholera outbreaks. However, the current manufacturer-recommended dosing regimen is challenging to implement programmatically and offers only short-term protection, particularly in young children, the most vulnerable population. This study aims to address this gap by generating evidence on the immunogenicity and durability of immunity across different dosing schedules. By evaluating the immune response, particularly in children, this trial will provide critical data to inform optimal dosing strategies. The findings will support the Kenyan Ministry of Health in enhancing the impact of preventive OCV campaigns and improving long-term cholera control efforts in endemic regions.
Risks and Benefits
Known Potential Risks
Associated with oral vaccine administration:
Mild to moderate side effects, such as gastrointestinal discomfort, nausea, or diarrhea, may occur.
Serious allergic reactions, though rare, are a possibility and will be monitored.
Behaviour Change:
Although the literature on preventative behaviors suggest that it is highly unlikely, it is theoretically possible that participants might alter their risk behaviors assuming they are protected post-vaccination. They will be advised to continue following cholera prevention measures.
Specific Risks from Euvichol-S Vaccine:
Euvichol-S is generally well-tolerated. In the phase 3 clinical trial, of 1,595 participants who received the product, 151 (\<10%) reported any adverse event. The most common adverse events after vaccination were pyrexia (3.6%) and nasopharyngitis (2.2%).
The specific risks associated with different dosing intervals of Euvichol-S are under study. Participants will be informed of any known risks related to the vaccine.
Community Perceptions:
Participation in the vaccine trial might affect community perceptions towards the participant. Efforts will be made to maintain confidentiality and manage community relations carefully.
Associated with Venous Puncture:
While generally safe, venous puncture can result in discomfort or minor reactions such as pain at the puncture site, bruising, or occasional bleeding. Participants will receive instructions to minimize and manage these potential effects.
Vaccine efficacy risks:
One dose of oral cholera vaccine offers short-term protection against cholera, necessitating a second dose for longer-term immunity. Our hypothesis is that longer intervals between doses (3-months and 1 year) will result in similar long-term immunity at 1 year after the delayed booster dose as with the standard 2-week dosing interval at 1 year after the booster dose; however, it is possible that protection against cholera may diminish prior to the 2nd dose. These risks will be clearly communicated to participants, and any new information regarding vaccine efficacy will be communicated as it becomes available.
Known Potential Benefits Euvichol-S oral cholera vaccine induces a protective immune response against cholera. Thus, participants in this study who receive the vaccine are expected to have a lower risk of cholera compared to those who are not enrolled in the trial and do not receive immunization. Additionally, participants in this trial will receive the vaccine before it becomes widely available through government vaccination campaigns. This early access to the vaccine provides an immediate benefit in reducing their risk of cholera infection. Furthermore, this study aims to enhance the understanding of cholera vaccination strategies, potentially leading to more effective public health interventions against cholera globally.
Assessment of Potential Risks and Benefits
The trial balances the mild to moderate side effects and the rare but serious risks of allergic reactions from the Euvichol-S oral cholera vaccine against the expected benefit of reduced cholera risk among participants. While there are uncertainties regarding the longevity of protection, especially between dosing intervals, the study is critical for optimizing vaccination schedules and enhancing global cholera prevention strategies.
Objectives and Endpoints The primary objective is to assess and compare the immune response, specifically plasma vibriocidal GMT, two weeks post-second dose of Euvichol-S, across three dosing intervals: 2-weeks, 3-months and 1-year. Our secondary objectives expand on this by evaluating seroconversion, immune response within different age groups, monitoring long-term GMT differences, assessing cholera incidence, and documenting the vaccine's safety profile over extended dosing intervals. Additionally, our exploratory objectives include, analyzing V. cholerae O-specific polysaccharide (OSP)-specific plasma antibody, circulating gut-homing plasmablasts (a surrogate marker for the mucosal immune response), and memory B cell response magnitude and dynamics, to gain comprehensive insights into the vaccine's immunogenicity over 18 months.
Primary Objective To assess and compare the immune response to Euvichol-S, measured by plasma vibriocidal geometric mean titer (GMT) two weeks after the second vaccine dose, across different dosing intervals in participants aged 1 year and older.
Hypotheses:
The immune response to a three-month or twelve-month dosing interval of Euvichol-S is non-inferior to the recommended two-week interval in participants aged 1 year and older two weeks after the second dose.
This non-inferiority persists within specific age groups: young children (1-4 years), older children (5-14 years), and adults (15+ years), as measured at 6 months, 12 months, and 18 months after enrollment.
Secondary Objectives To compare plasma vibriocidal GMT across different dosing intervals within specific age groups.
To evaluate vibriocidal antibody seroconversion in relation to dosing intervals among all participants and within each age group.
To monitor and document the changes in vibriocidal GMT over an 18-month follow-up period, comparing between dosing interval groups and within age groups.
To assess and compare the incidence of cholera disease over an 18-month follow-up, focusing on the association with age groups and dosing intervals.
To evaluate and describe the safety and tolerability profile of extended dosing intervals of Euvichol-S.
Exploratory Objectives Assess and compare the following measures a) among all study participants and b) within each age group: Anti-O-specific polysaccharide (OSP) IgA and IgG responses in plasma over an 18-month follow-up period
Circulating gut-homing anti-OSP plasmablasts at baseline and 5 days after each dose of vaccine in a subcohort of children under 15 years Circulating anti-OSP memory B cells at baseline and 14 days after booster doses after each dose of vaccine in a subcohort of children under 15 years Assess and compare the persistence of plasma anti-OSP and vibriocidal immune response over an 18-month follow-up period by age group and dosing interval.
Cholera Disease Incidence Comparison: This involves comparing the incidence of cholera over 18 months across different age groups and dosing intervals. It is a direct measure of the vaccine's effectiveness in preventing the disease in the real-world setting.
Safety Profile Assessment: Investigators will record and analyze adverse events, spanning 18 months from the initial vaccination to the final follow-up, to assess the vaccine's safety over different dosing schedules.
83 studies on the registry are indexed under Cholera; 16 are open to participants now.
This study's planned enrollment of 1,071 is above the median of 262 across 72 interventional studies indexed under Cholera.
Browse Cholera studies →Albert B. Sabin Vaccine Institute is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must be in good health, as determined by medical history, physical examination, and the clinical judgment of the investigators. Clinical judgment will consider factors such as the absence of acute illness or, uncontrolled or severe chronic conditions that may affect participation in the study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received the second OCV dose per the recommended dosing schedule 2 weeks after the initial dose.
Drug: Euvichol-S Oral Cholera Vaccine
Participants received the second OCV dose 3 months after the initial dose.
Drug: Euvichol-S Oral Cholera Vaccine
Participants received the second OCV dose 12 months after the initial dose.
Drug: Euvichol-S Oral Cholera Vaccine
Parallel-group, phase IV, open-label, randomized, non-inferiority trial Arms: Three distinct arms, each balanced in a 1:1:1 ratio: Standard Dosing Arm (Two Weeks Interval) Extended Interval Dosing Arm (Three Months Interval) Annual Booster Dosing Arm (Twelve Months Interval) Each dosing arm will have the following three age strata: Children aged 1-4 years Children aged 5-14 years Adults aged 15 years and older
Also known as: cholera: inactivated oral, Euvichol
To assess and compare the immune response to Euvichol-S, measured by plasma vibriocidal geometric mean titer (GMT) two weeks after the second vaccine dose, across different dosing intervals in participants aged 1 year and older.
Plasma Vibriocidal GMT Measurement: Measurement of the concentration of plasma vibriocidal GMT two weeks after administering the second dose of Euvichol-S. Vibriocidal antibodies are the best-established immune correlate of protection against cholera. The GMT, a statistical representation of the antibody levels in the study population, is an objective and quantifiable measure of the vaccine's immunogenicity. By comparing GMT values across different dosing intervals, we aim to validate the immunogenicity of extended dosing schedules, assessing if they are as effective at eliciting a protective immune response as the standard two-week interval. This assessment will be crucial in guiding future vaccination strategies, particularly in resource-limited settings where scheduling flexibility can significantly impact public health outcomes.
Time frame: Plasma vibriocidal GMT measurement 2-weeks after the 2nd vaccine dose of Euvichol-S in participants 1+ years for the Comparator Arm (2nd dose at 2 weeks), Intervention Arm 1 (2nd dose at 3-months), and Intervention Arm 2 (2nd dose at 1-year)
Plasma Vibriocidal GMT
Plasma Vibriocidal GMT Comparison: Compare the concentration of plasma vibriocidal geometric mean titer (GMT) across various dosing intervals within distinct age groups to determine whether the average antibody levels within each age strata varies by the vaccine dosing schedule. Vibriocidal Antibody Seroconversion Evaluation: Assess the proportion of vaccinees who had a 4-fold or greater rise in vibriocidal titers after vaccination, indicating the development of an immune response to the vaccine. Longitudinal GMT Changes Monitoring: Describe plasma vibriocidal GMT over an 18-month period: two weeks post-vaccination and also at 6, 12, and 18 months post-enrollment; this outcome tracks the persistence and variation of GMT by dosing interval and age to understand the duration and stability of the immune response elicited by the vaccine. Cholera Disease Incidence Comparison: Compare the incidence of cholera over 18 months across different age groups and dosing intervals.
Time frame: Plasma vibriocidal GMT over an 18-month period: two weeks post-vaccination and also at 6, 12, and 18 months post-enrollment.
Exploratory Objective 1 - Anti-O-specific polysaccharide (OSP) IgA responses in plasma
Assessment of plasma Anti-OSP IgA Responses: Measure concentration of plasma levels of antibodies (IgA) against the V. cholerae O-specific polysaccharide (OSP) for insights into the specific immune response elicited by the vaccine that are known to correlate with protection. Persistence of Plasma Anti-OSP IgA: Measure how long the plasma immune response persistence. Comparative Analysis Based on Baseline Vibriocidal Titers
Time frame: Anti-OSP IgA over an 18-month period: two weeks post-vaccination and also at 6, 12, and 18 months post-enrollment.
Exploratory Objective 2 - Anti-O-specific polysaccharide (OSP) IgG responses in plasma
Assessment of plasma Anti-OSP IgG Responses: Measure concentration of plasma levels of antibodies (IgG) against the V. cholerae O-specific polysaccharide (OSP) for insights into the specific immune response elicited by the vaccine that are known to correlate with protection. Persistence of Plasma Anti-OSP IgG: Measure how long the plasma immune response persistence. Comparative Analysis Based on Baseline Vibriocidal Titers
Time frame: Anti-OSP IgG over an 18-month period: two weeks post-vaccination and also at 6, 12, and 18 months post-enrollment.
Exploratory Objective 3 - PBMC Sub-cohort: Circulating gut-homing anti-OSP memory B cells (MBCs)
Peripheral blood mononuclear cells (PBMC) Sub-cohort - Evaluate the presence and quantity of cholera-specific anti-OSP memory B cells (MBCs) specific to V. cholerae OSP at baseline and after booster doses, which are crucial for long-term immunity, as they are responsible for a quicker and more robust response upon re-exposure to the pathogen.
Time frame: MBC at baseline, 14 days after 2nd dose, and 12 months after 1st dose (1-year interval group) in sub-cohort of children 1-14 years.
Exploratory Objective 4: PBMC Sub-cohort - Mucosal Antibody Secreting Cell (ASC)
Peripheral blood mononuclear cells (PBMC) Sub-cohort - Evaluate the presence and quantity of cholera-specific mucosal gut-homing anti-OSP plasmablasts, a type of antibody-secreting cell (ASC) at baseline and after booster doses.
Time frame: Mucosal ASC at baseline and 5 days after each dose in sub-cohort of children 5-14 years.
Started Oct 2025 (actual). Primary completion is estimated for Jun 2028, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Albert B. Sabin Vaccine Institute